{"id":105733,"date":"2025-08-28T09:29:31","date_gmt":"2025-08-28T15:29:31","guid":{"rendered":"https:\/\/losperiodistas.com.mx\/portal\/?p=105733"},"modified":"2025-08-28T09:29:32","modified_gmt":"2025-08-28T15:29:32","slug":"eli-lilly-esta-lista-para-solicitar-luz-verde-a-su-pastilla-contra-la-obesidad-tras-alcanzar-los-objetivos-del-estudio-wsj","status":"publish","type":"post","link":"https:\/\/losperiodistas.com.mx\/portal\/eli-lilly-esta-lista-para-solicitar-luz-verde-a-su-pastilla-contra-la-obesidad-tras-alcanzar-los-objetivos-del-estudio-wsj\/","title":{"rendered":"Eli Lilly est\u00e1 lista para solicitar luz verde a su pastilla contra la obesidad tras alcanzar los objetivos del estudio | WSJ"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Eli Lilly afirma que ahora cuenta con el paquete completo de datos cl\u00ednicos que necesita para iniciar las presentaciones regulatorias globales para orforglipron este a\u00f1o.<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/losperiodistas.com.mx\/portal\/wp-content\/uploads\/2025\/08\/im-18482420-copia-1024x683.jpg\" alt=\"\" class=\"wp-image-105734\" srcset=\"https:\/\/losperiodistas.com.mx\/portal\/wp-content\/uploads\/2025\/08\/im-18482420-copia-1024x683.jpg 1024w, https:\/\/losperiodistas.com.mx\/portal\/wp-content\/uploads\/2025\/08\/im-18482420-copia-300x200.jpg 300w, https:\/\/losperiodistas.com.mx\/portal\/wp-content\/uploads\/2025\/08\/im-18482420-copia-768x512.jpg 768w, https:\/\/losperiodistas.com.mx\/portal\/wp-content\/uploads\/2025\/08\/im-18482420-copia.jpg 1400w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">Eli Lilly afirm\u00f3 que el estudio de fase 3 de orforglipron en adultos con obesidad o sobrepeso y diabetes tipo 2 cumpli\u00f3 con los criterios de valoraci\u00f3n primarios y todos los criterios de valoraci\u00f3n secundarios clave en las tres dosis.\u00a0Foto:\u00a0Mike Blake\/Reuters<\/figcaption><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-vivid-red-color has-text-color has-link-color has-medium-font-size wp-elements-517b0d905b6b1ad6de2a35866da201b5\"><strong>Por Colin Kellaher \/ The Wall Street Journal<\/strong><\/p>\n\n\n\n<p><a href=\"https:\/\/www.wsj.com\/market-data\/quotes\/LLY\" target=\"_blank\" rel=\"noreferrer noopener\">Eli Lilly&nbsp;<\/a><a href=\"https:\/\/www.wsj.com\/market-data\/quotes\/LLY\">LLY&nbsp;-0,63&nbsp;%decrease; red down pointing triangle<\/a>dijo que un tercer estudio de etapa avanzada de su p\u00edldora experimental contra la obesidad alcanz\u00f3 sus objetivos clave, allanando el camino para que la empresa farmac\u00e9utica comience las presentaciones regulatorias.<\/p>\n\n\n\n<p>Eli Lilly dijo el martes que el estudio de Fase 3 de orforglipron en adultos con obesidad o sobrepeso y diabetes tipo 2 cumpli\u00f3 con los criterios de valoraci\u00f3n primarios y todos los secundarios clave en las tres dosis, mostrando una p\u00e9rdida de peso significativa, reducciones significativas de A1C y mejoras en los factores de riesgo cardiometab\u00f3lico a las 72 semanas.<\/p>\n\n\n\n<p>La compa\u00f1\u00eda de Indian\u00e1polis dijo que los participantes del estudio perdieron un promedio de 22,9 libras, o 10,5% de su peso corporal, con la dosis m\u00e1s alta, y que la A1C, una medida de los niveles de az\u00facar en sangre, se redujo en un promedio de 1,8%.<\/p>\n\n\n\n<p>Eli Lilly dijo que orforglipron tambi\u00e9n mostr\u00f3 un perfil de seguridad consistente con los medicamentos inyectables GLP-1, como sus exitosos medicamentos Mounjaro y Zepbound.<\/p>\n\n\n\n<p>Eli Lilly dijo que ahora tiene el paquete de datos cl\u00ednicos completo que necesita para iniciar las presentaciones regulatorias globales para orforglipron este a\u00f1o.<\/p>\n\n\n\n<p>Se espera que Orforglipron se convierta en un \u00e9xito de ventas si los reguladores aprueban su venta. Los analistas de Morgan Stanley hab\u00edan afirmado previamente que, en su escenario alcista, el uso de la p\u00edldora tanto para la obesidad como para la diabetes podr\u00eda generar ventas anuales de hasta 40&nbsp;000 millones de d\u00f3lares para 2033.<\/p>\n\n\n\n<p>Sin embargo, Eli Lilly inform\u00f3 a principios de este mes los resultados de un estudio separado de Fase 3 que no alcanzaron lo que algunos analistas hab\u00edan pronosticado, lo que merm\u00f3 el entusiasmo de Wall Street.<\/p>\n\n\n\n<p>Las acciones de Eli Lilly, que cayeron un 14% el 7 de agosto despu\u00e9s de los resultados del estudio anterior, subieron recientemente un 1,5% a 705,50 d\u00f3lares en las operaciones previas a la apertura del mercado.<\/p>\n\n\n\n<p>Peter Loftus contribuy\u00f3 a este art\u00edculo.<\/p>\n\n\n\n<p>Fuente: <a href=\"https:\/\/www.wsj.com\/health\/pharma\/eli-lilly-ready-to-seek-obesity-pill-green-light-after-study-hits-goals-4915f3c8?mod=health_lead_pos2\">https:\/\/www.wsj.com\/health\/pharma\/eli-lilly-ready-to-seek-obesity-pill-green-light-after-study-hits-goals-4915f3c8?mod=health_lead_pos2<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly afirma que ahora cuenta con el paquete completo de datos cl\u00ednicos que necesita para iniciar las presentaciones regulatorias [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":105734,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[8],"tags":[41259,41260],"class_list":["post-105733","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias","tag-laboratorios-eli-lilly","tag-pastilla-contra-la-obesidad"],"_links":{"self":[{"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/posts\/105733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/comments?post=105733"}],"version-history":[{"count":1,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/posts\/105733\/revisions"}],"predecessor-version":[{"id":105735,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/posts\/105733\/revisions\/105735"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/media\/105734"}],"wp:attachment":[{"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/media?parent=105733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/categories?post=105733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/tags?post=105733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}